PolTREG S.A. signed an agreement with the U.S. AZTherapies Inc. with Boston (AZT) on the development and commercialization of therapies based on CAR-Treg cells for the treatment of autoimmune neurological diseases.

2021-11-17

PolTREG S.A. signed an agreement with the U.S. AZTherapies Inc. with Boston (AZT) on the development and commercialization of therapies based on CAR-Treg cells for the treatment of autoimmune neurological diseases.

Thanks to cooperation with AZTherapies, PolTREG will expand the pipeline of projects, accelerate the development of technology and has the chance to be the global leader in the dynamically developing CAR-Treg segment highly valued by the market.

AZT grants PolTREG an exclusive license to commercialize CAR-Treg therapy in therapeutic and prophylactic use throughout the world and licenses to develop, manufacture and use CAR-Treg therapy for clinical trials.

PolTREG plans to initiate a clinical trial of 1/2 CAR-Treg therapy in the first half of 2023 in the treatment of one of neurological autoimmune diseases (e.g. amytrophic lateral sclerosis). The completion of the phase 1/2 trial in the CAR-Treg treatment area is planned for 2025. The potential of the CAR-Treg therapy market in the treatment of ALS is ~ USD 12 billion.

Download the press release

See other news

2024-09-26

PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases

See

2024-09-16

China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis

See

2024-09-11

Join us for the PolTREG H1 2024 financial results webinar!

See

2024-09-09

PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence

See

2024-07-24

The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.

See

2024-06-25

PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk

See

2024-06-24

Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes

See

2024-06-13

PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment

See

PolTREG S.A. signed an agreement with the U.S. AZTherapies Inc. with Boston (AZT) on the development and commercialization of therapies based on CAR-Treg cells for the treatment of autoimmune neurological diseases.

See other news

About Us

Our Science

Patients